Viatris Competitive Intelligence & Landscape

Viatris (viatris.com) is a global healthcare company dedicated to empowering people worldwide to live healthier lives at every stage. Formed in November 2020 through the combination of Mylan and Upjohn, Viatris focuses on expanding access to medicines, innovating to meet patient needs, and serving as a trusted partner for global healthcare communities [viatris.com/en/about-us]. The company aims to deliver healthcare solutions that are effective, scalable, and enduring, providing both new and more affordable medicines, ensuring a resilient supply of therapies, and pursuing bold innovation [viatris.com/en].

Viatris operates by bridging the gap between generics and brands, offering a diverse portfolio that includes both to holistically address global healthcare needs [www.viatris.com/-/media/project/common/viatris/pdf/viatris-corporate-fact-sheet---september-2023.pdf]. Their core products and services involve developing and delivering high-quality medicines across various therapeutic areas, with billions of doses sold across over 165 countries [viatris.com, www.viatris.com/-/media/project/common/viatris/pdf/viatris-corporate-fact-sheet---september-2023.pdf]. The company is committed to sustainability, having been recognized on TIME’s World’s Most Sustainable Companies List and Newsweek’s World’s Greenest Companies list [viatris.com/en/careers].

Headquartered at 1000 Mylan Boulevard, Canonsburg, Pennsylvania, 15317, Viatris takes seriously the trust placed in them by shareholders to fulfill their global healthcare mission [investor.viatris.com/static-files/cd6d2cf4-7fbe-4e3a-b7fb-fc044e2e5e4e, investor.viatris.com/investor-relations]. They maintain an active investor relations presence, providing financial results, stock information, and news on their latest developments, such as new drug applications [investor.viatris.com, investor.viatris.com/investor-relations].

Viatris employs thousands of people in manufacturing, science, and technology jobs within the U.S., leveraging best-in-class manufacturing and commercial capabilities [www.viatris.com/en-us/lm/united-states].

Viatris (viatris.com) offers a comprehensive and diverse portfolio of medicines, encompassing generics, established brands, and biosimilars, along with over-the-counter products [viatris.com/en-us/lm/united-states/us-products/productcatalog]. Their products cover a wide range of therapeutic areas and are accessible in over 165 countries and territories globally [viatris.com/en/products]. The company emphasizes providing access to high-quality medicines that address various health needs, from acute conditions to chronic diseases, supporting individuals throughout their life's journey [viatris.com/-/media/project/common/viatris/pdf/viatris-corporate-fact-sheet---september-2023.pdf].

Viatris offers an extensive selection of generic medicines, including both complex and branded generics. These generics are designed to be therapeutically equivalent to their brand-name counterparts, offering the same clinical benefits but often at a lower cost, which contributes to important savings for patients and the healthcare system. Examples of their generic offerings include Alprazolam Tablets (generic for Xanax®) and Medroxyprogesterone Acetate Tablets (generic for Provera®) [viatris.com/-/media/Project/Common/Viatris/PDF/US/US_Greenstone_Upjohn_Product-Chart.pdf?hcp=true, viatris.com/en/products/generics].

Among their branded products, Viatris lists medications like CADUET (amlodipine, atorvastatin) in various strengths and presentations [viatris.com/-/media/project/common/viatris/pdf/us/us_upjohn_product-chart.pdf?hcp=true]. Other specific brand examples found include DYMISTA Nasal Spray and ELIDEL Cream in regions like Hong Kong [viatris.com/-/media/project/common/viatris/pdf/hong_kong/viatris-products-in-hong-kong.pdf]. The company's product strategy is to offer a broad range across multiple therapeutic areas, reflecting their commitment to diverse healthcare needs [viatris.com/-/media/project/common/viatris/pdf/viatris-corporate-fact-sheet---september-2023.pdf].

Regarding pricing and patient support, Viatris provides a Patient Assistance Program that offers certain medicines free of charge to patients who demonstrate financial need [viatris.com/en-us/lm/united-states/patient-assistance-program]. While specific pricing plans or tiers for individual medications are not publicly detailed on their corporate website, the availability of generics suggests a focus on providing more affordable medicine options compared to brand-name drugs [viatris.com/en/products/generics]. The company's approach seems to center on accessible healthcare solutions rather than subscription-based pricing models common in other industries.

Viatris actively recruits a global workforce dedicated to advancing its mission of improving healthcare worldwide, emphasizing an inclusive culture and providing competitive benefits to its employees [https://www.viatris.com/en/about-us/global-sustainability/our-people]. The company is committed to offering opportunities for its staff to achieve their full potential [https://www.viatris.com/en/about-us/global-sustainability/our-people].

Job seekers interested in Viatris can explore available positions by choosing their location on the company's dedicated careers page [https://www.viatris.com/en/careers/working-at-viatris]. Opportunities may include remote and flexible roles [https://www.viatris.com/en/careers/locations-near-you]. The official source for all Viatris job postings is viatris.com, though authorized third-party career websites may also list openings [https://www.viatris.com/en/careers/careers-faqs]. Current employees are also encouraged to find new opportunities within the company via the intranet [https://www.viatris.com/en/careers].

Viatris promotes Equal Opportunity and Inclusion in its hiring practices [https://www.viatris.com/en/careers/equal-opportunity-and-inclusion]. The company's consistent and broad recruitment efforts across various global locations, coupled with its emphasis on internal career progression, signal a strategy focused on sustained growth and a commitment to nurturing its human capital to meet its global healthcare objectives.

Viatris (viatris.com) demonstrates a solid financial standing, with reported total revenues of $14.3 billion for the full year 2025 and $3.7 billion for the fourth quarter of 2025, meeting or exceeding its financial guidance across key metrics for the year [https://investor.viatris.com/news-releases/news-release-details/viatris-reports-fourth-quarter-and-full-year-2025-financial/]. In 2024, the company reported total revenues of $14.7 billion, a U.S. GAAP net loss of $(634) million, and adjusted EBITDA of $4.7 billion [https://investor.viatris.com/news-releases/news-release-details/viatris-reports-fourth-quarter-and-full-year-2024-financial/]. For 2023, Viatris achieved total revenues of $15.4 billion and U.S. GAAP net earnings of $54.7 million [https://investor.viatris.com/news-releases/news-release-details/viatris-reports-fourth-quarter-and-full-year-2023-financial/].

The company maintains a consistent approach to capital allocation, returning over $1 billion to shareholders in 2025 and anticipating a balanced approach for 2026 [https://investor.viatris.com/news-releases/news-release-details/viatris-reports-fourth-quarter-and-full-year-2025-financial/]. In 2025, shareholder returns included $500 million in share repurchases [https://newsroom.viatris.com/2025-11-06-Viatris-Reports-Third-Quarter-2025-Results-and-Updates-2025-Financial-Guidance].

Viatris also provides financial guidance for 2026, positioning itself for sustainable growth [https://newsroom.viatris.com/2026-02-26-Viatris-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results].

Regarding M&A activity, Viatris completed the acquisition of Aculys in 2025, which included rights to Pitolisant and Spydia in Japan and other Asian markets [https://newsroom.viatris.com/2025-11-06-Viatris-Reports-Third-Quarter-2025-Results-and-Updates-2025-Financial-Guidance]. The company also anticipates regulatory decisions for six product candidates in 2026, indicating ongoing pipeline development and potential for future growth [https://newsroom.viatris.com/2026-02-26-Viatris-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results].

Viatris regularly releases financial and regulatory documents, including SEC filings, which are available on its investor relations website [https://investor.viatris.com/financial-and-filings/sec-filings/].

Viatris actively engages in investor-focused events, participating in and presenting at various healthcare conferences to keep stakeholders informed about its financial results, strategic goals, and stock performance [https://ir.viatris.com/events-and-presentations]. These events include both upcoming and archived presentations, providing comprehensive resources for investors.

The company has a consistent presence at major industry conferences. For example, Viatris is scheduled to present at the Bank of America Securities 2026 Healthcare Conference on May 12, 2026 [https://investor.viatris.com/news-releases/news-release-details/viatris-present-bank-america-securities-2026-healthcare] and participated in the BofA Securities 2025 Healthcare Conference on May 13, 2025 [https://investor.viatris.com/events/event-details/bofa-securities-2025-healthcare-conference]. They also have a history of attending the JPMorgan Healthcare Conference, with participation in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 [https://investor.viatris.com/events/event-details/jpmorgan-44th-annual-healthcare-conference].

Viatris also participates in other significant investor gatherings, such as the Piper Sandler 37th Annual Healthcare Conference in December 2025 [https://investor.viatris.com/news-releases/news-release-details/viatris-participate-upcoming-investor-conferences-2] and the UBS Global Healthcare Conference 2025 on November 11, 2025 [https://newsroom.viatris.com/2025-10-13-Viatris-to-Participate-in-Upcoming-Investor-Conferences]. These participations often involve fireside chats and presentations, offering detailed insights into the company's operations and outlook.